Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Breakout Charts -- Ignore unavailable to you. Want to Upgrade?

To: j.j. jingleheimerschmidt who wrote (324)	2/18/2000 4:12:00 AM
From: j.j. jingleheimerschmidt	Read Replies (1) \| Respond to of 421

I almost forgot about this one. This one looks like a medium (1/2 year) to long term (1 year+) hold for me: SCLN (8 15/16) Sciclone Pharmaceuticals. SciClone is a global biopharmaceutical company that acquires, develops and commercializes specialist-oriented drugs for treating chronic and life-threatening diseases. For the 9 months ended 9/99, revenues totalled $6.4M, up from $2.5M. Net loss applicable to Common decreased 67% to $4.9M. Results reflect increased sales of ZADAXIN due to greater distribution in China, partially offset by increasedpayroll and advertising expenses. REVENUE Quarters 1996 1997 1998 1999 MAR 126 671 654 1,777 JUN 122 623 801 2,108 SEP 152 673 1,006 2,513 DEC 303 256 1,264 2,999* Totals 703 2,223 3,725 9,397 MKT cap ~ 223 million Zadaxin should pull in good revenue for them. I'm not in yet, but look to get in tomorrow morning unless it breaks down. I'll add it to the portfolio. siliconinvestor.com JJJ